Icatibant Ethypharm

Icatibant, the active ingredient in Icatibant Ethypharm, is a bradykinin B2 receptor antagonist presented as a 30 mg/1 mL solution for injection for subcutaneous use. It treats acute attacks of hereditary angioedema in patients with C1‑inhibitor deficiency. The formulation is approved for use in the European Union and is administered by healthcare professionals trained in subcutaneous injection techniques.

GNH USA supplies Icatibant Ethypharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality, regulatory compliance, and reliable cold‑chain logistics for injectable biologics.

Icatibant acts on the bradykinin pathway, providing targeted therapy for hereditary angioedema and related swelling disorders.

Acute attacks of hereditary angioedema (HAE) in patients with C1‑inhibitor deficiency (type I or II): Icatibant rapidly reverses bradykinin‑induced vascular leakage, leading to a prompt decrease in swelling of the skin, gastrointestinal tract, and upper airway, thereby alleviating pain and reducing the risk of life‑threatening airway obstruction. Hereditary angioedema type I and II episodes: the drug offers rapid symptom control by blocking bradykinin‑mediated edema, helping to restore normal function of affected tissues.

Icatibant may cause a range of adverse reactions, most of which are related to the injection site or systemic response.

Common Side Effects: - Injection site pain - Redness or erythema at the injection site - Nausea

Serious or Rare Side Effects: - Anaphylaxis (severe allergic reaction) - Angioedema unrelated to hereditary angioedema - Significant hypotension

Use of Icatibant requires careful assessment of patient-specific factors and monitoring for adverse events. - Pregnancy: safety not established; prescribe only if benefit outweighs potential risk. - Breastfeeding: unknown safety profile; consider risk versus benefit. - Renal impairment: no dose adjustment required, but monitor for accumulation. - Concomitant ACE inhibitors: may increase bradykinin levels; observe for signs of angioedema. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant can interact with other agents that influence bradykinin metabolism or immune response.

Major Interactions (Avoid): - ACE inhibitors (e.g., enalapril, lisinopril) - Angiotensin II receptor blockers (e.g., losartan, valsartan) - Neprilysin inhibitors (e.g., sacubitril)

Moderate Interactions (Monitor Closely): - Estrogen‑containing therapies (may increase HAE attack frequency) - Other subcutaneous injections administered at the same site (potential for altered absorption)